INT36286

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1987
Last Reported 2010
Negated 3
Speculated 1
Reported most in Body
Documents 33
Total Number 34
Disease Relevance 10.11
Pain Relevance 3.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Cd3e) signal transducer activity (Cd3e)
Anatomy Link Frequency
T cells 13
lymphocytes 2
bone marrow 1
artery 1
blood vessels 1
Cd3e (Mus musculus)
Pain Link Frequency Relevance Heat
Substantia nigra 98 99.92 Very High Very High Very High
rheumatoid arthritis 304 99.28 Very High Very High Very High
Inflammation 392 98.88 Very High Very High Very High
Bioavailability 31 98.40 Very High Very High Very High
Opioid 3 90.64 High High
Cannabinoid 1 83.84 Quite High
chemokine 222 82.04 Quite High
cINOD 8 81.16 Quite High
cytokine 452 80.24 Quite High
Spinal cord 17 80.20 Quite High
Disease Link Frequency Relevance Heat
Cancer 204 100.00 Very High Very High Very High
Coronary Artery Disease 53 100.00 Very High Very High Very High
Adhesions 45 100.00 Very High Very High Very High
Rheumatoid Arthritis 323 99.28 Very High Very High Very High
INFLAMMATION 375 98.88 Very High Very High Very High
Infection 174 96.12 Very High Very High Very High
Death 212 95.40 Very High Very High Very High
Atherosclerosis 6 95.08 Very High Very High Very High
General Immunology 3 94.40 High High
Solid Tumor 4 93.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Approximately 106 bone marrow cells from each mouse were incubated with rabbit serum for 40 minutes on ice, washed with PBS containing 0.1% BSA, and subsequently allowed to react for 50 minutes with antibodies to mouse Thy 1.2 or CD3 and CD45R/B220 (Pharmingen or Sigma) labeled with FITC and PE.
CD3 Binding (react) of in bone marrow
1) Confidence 0.36 Published 2001 Journal BMC Immunol Section Body Doc Link PMC37547 Disease Relevance 0.15 Pain Relevance 0
In contrast to the obvious assumption that most of the antibody in the peripheral blood may be bound to T cells via its CD3 binding arm spiking experiments revealed that 80–90% of catumaxomab were not cell bound (data not shown).
CD3 Binding (binding) of in T cells
2) Confidence 0.28 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 0.53 Pain Relevance 0.03
is rate-limiting, thereby regulating the amount of TCR/CD3 complex expressed at the cell surface.8,9 In NK cells, the TCR?
CD3 Binding (complex) of in NK cells
3) Confidence 0.24 Published 2007 Journal Blood Section Body Doc Link PMC1939810 Disease Relevance 0 Pain Relevance 0
This can be readily explained by the intermediate affinity of catumaxomab to CD3 (KD= 4.4 nm) which does not allow quantitative T-cell binding at very low antibody concentrations.
CD3 Binding (binding) of in T-cell
4) Confidence 0.22 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 0.44 Pain Relevance 0.03
Catumaxomab has binding sites for EpCAM on tumour cells, for CD3 on T-cells, and for Fc?
CD3 Binding (sites) of in T-cells associated with cancer
5) Confidence 0.22 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 0.62 Pain Relevance 0.05
We detected prominent recruitment of neutrophils (CD11clo Gr1+) and CD8+T cells (CD3+CD4-CD8+) in mice inoculated at four weeks of age.
CD3 Binding (recruitment) of in T cells
6) Confidence 0.19 Published 2010 Journal Virol J Section Body Doc Link PMC2993675 Disease Relevance 0.55 Pain Relevance 0.16
Similarly, staining for CD3, CD4, CD8 or B220 was always negative in the CVOs of healthy mice (Table 1).


CD3 Binding (staining) of
7) Confidence 0.18 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1262737 Disease Relevance 0.25 Pain Relevance 0
antigen recognition chains devoid of signaling motifs associated with the invariant chain subunits CD3?
CD3 Binding (associated) of
8) Confidence 0.16 Published 2007 Journal Blood Section Body Doc Link PMC1939810 Disease Relevance 0.17 Pain Relevance 0.04
The strong down-regulation of CD25 expression of CD3-activated T cells by Gal-4 proves the biological consequence of the Gal-4 binding to the CD3 complex.
CD3 Binding (binding) of in T cells
9) Confidence 0.15 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440804 Disease Relevance 0.06 Pain Relevance 0.06
Primary antibodies included (1) anti-CD3 (monoclonal mouse IgG2a, Biocarta, Hamburg, Germany) to mark mucosal T lymphocytes, (2) anti-IgA antibody (?
CD3 Binding (mark) of in T lymphocytes
10) Confidence 0.13 Published 2007 Journal BMC Gastroenterol Section Body Doc Link PMC1995200 Disease Relevance 0.45 Pain Relevance 0.14
cells did not change, the percentage of CD3?
CD3 Neg (not) Binding (percentage) of
11) Confidence 0.13 Published 2010 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2816392 Disease Relevance 0 Pain Relevance 0
PBMC were activated with plate-bound CD3 mAb and incubated in the presence or absence of 100 µg/ml Gal-4 for 72 h.
CD3 Binding (bound) of
12) Confidence 0.11 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440804 Disease Relevance 0 Pain Relevance 0
We could demonstrate that Gal-4 potently binds to activated T cells at the CD3 region which is translated in a potent inhibition of cell cycle progression and induction of antigen-induced cell death.
CD3 Binding (binds) of in T cells associated with death
13) Confidence 0.11 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440804 Disease Relevance 1.32 Pain Relevance 0.37
Gal-4 did not bind to unstimulated, but to anti-CD3 and anti-CD2 stimulated PBT and LPT, respectively.
CD3 Neg (not) Binding (bind) of
14) Confidence 0.11 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2440804 Disease Relevance 0 Pain Relevance 0
Following incubation with anti-CD3?
CD3 Binding (incubation) of
15) Confidence 0.10 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2780913 Disease Relevance 0.09 Pain Relevance 0
Graded antigen stability occurred: CD3 most stable, CD8 least, and CD4 intermediate.
CD3 Binding (intermediate) of
16) Confidence 0.10 Published 1987 Journal J. Histochem. Cytochem. Section Abstract Doc Link 3309048 Disease Relevance 0 Pain Relevance 0.06
Cells were stimulated to proliferate in serum-free medium by cross-linking the T cell receptor using plate-coated anti-CD3-epsilon, then 3H-thymidine uptake and cell number were measured at 48 and 72 hr.
anti-CD3-epsilon Binding (cross-linking) of in T cell
17) Confidence 0.08 Published 1995 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7791081 Disease Relevance 0 Pain Relevance 0.25
Characterization of the cells for their immunophenotypic markers by fluorescent-activated cell sorting (FACS) showed that they were negative for cell lineage markers CD45, CD14, CD34, CD19, CD3, Flk-1 and positive for typical MSC surface proteins Sca-1, CD105, CD29, CD90, CD73 and CD44 (Table 1).
CD3 Neg (negative) Binding (lineage) of
18) Confidence 0.07 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2270908 Disease Relevance 0.30 Pain Relevance 0
Characterization of the cells for their immunophenotypic markers by fluorescent-activated cell sorting (FACS) showed that they were negative for cell lineage markers CD45, CD14, CD34, CD19, CD3, Flk-1 and positive for typical MSC surface proteins Sca-1, CD105, CD29, CD90, CD73 and CD44 (Table 1).
CD3 Binding (negative) of
19) Confidence 0.07 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2270908 Disease Relevance 0.30 Pain Relevance 0
In some experiments, T cells purified by negative selection as above were cultured for 6 hours in wells precoated with antibodies to CD3 (UCHT1) and CD28 (CD28.2 clone), each coated at 5 ?
CD3 Binding (precoated) of in T cells
20) Confidence 0.06 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526593 Disease Relevance 0 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox